Quick Summary:
As the healthcare industry continues to evolve, the Global Xerostomia (Dry Mouth) Therapeutics Market presents far-reaching opportunities for key players and strategists. Currently estimated at a considerable US$704.1 Million, projections indicate promising growth, with a revised target of US$1 Billion by 2030. Comprising over-the-counter and prescription segments, the market promises significant gains in both areas, each exhibiting steady predicted growth over the next 8-year period.
Furthering its global scope, this report provides an insightful coverage of geographical markets beyond the US. China's market, driven by the world's second largest economy, is forecast to grow impressively at a CAGR of 7.4% in the period 2022 to 2030. There are also notable predictions for Japan, Canada, and Germany, each showing promising trajectories. Equip yourself with this crucial knowledge from competitors' market shares, to geographical presence, and more, crucial for informed strategic decision-making in this thriving market.
Global Xerostomia (Dry Mouth) Therapeutics Market to Reach $1 Billion by 2030
The global market for Xerostomia (Dry Mouth) Therapeutics estimated at US$704.1 Million in the year 2022, is projected to reach a revised size of US$1 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2022-2030. Over-the-Counter, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$603.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Prescription segment is readjusted to a revised 4.3% CAGR for the next 8-year period.
The U.S. Market is Estimated at $191.8 Million, While China is Forecast to Grow at 7.4% CAGR
The Xerostomia (Dry Mouth) Therapeutics market in the U.S. is estimated at US$191.8 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$209.5 Million by the year 2030 trailing a CAGR of 7.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.Select Competitors (Total 36 Featured) -
- 3M company
- Advanz Pharma Corp. Limited
- Bausch Health Companies Inc.
- Fresenius SE & Co. KGaA
- GlaxoSmithKline PLC
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Parnell Pharmaceuticals Inc.
- Pharmascience Inc (Pendopharm)
- Quest Products Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Xerostomia (Dry Mouth) Therapeutics?
What is the growth rate of the Global Market for Xerostomia (Dry Mouth) Therapeutics?
What is the forecasted size of the Global Market for Xerostomia (Dry Mouth) Therapeutics?
Who are the key companies in the Global Market for Xerostomia (Dry Mouth) Therapeutics?
| Report Attribute | Details |
|---|---|
| No. of Pages | 92 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 704.1 Million |
| Forecasted Market Value ( USD | $ 1000 Million |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- 3M company
- Advanz Pharma Corp. Limited
- Bausch Health Companies Inc.
- Fresenius SE & Co. KGaA
- GlaxoSmithKline PLC
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Parnell Pharmaceuticals Inc.
- Pharmascience Inc (Pendopharm)
- Quest Products Inc.
